Sean Stalfort

President

Sean Stalfort co-founded PBM Capital in 2010 and currently serves as President. He sources, structures, and oversees new biotech investment opportunities. Sean has been a founding investor or Board member in over 10 companies which went public including AveXis (acquired by Novartis for $8.7 billion), ArcherDx (acquired by Invitae for $1.4 billion), Dova (acquired by Sobi for over $900 million), Taysha Gene Therapies (NASDAQ: TSHA), Candel Therapeutics (NASDAQ: CADL), Verrica Pharmaceuticals (NASDAQ: VRCA), and Acumen Therapeutics (NASDAQ: ABOS) and several private companies including Curadel, Blue Marlin and MG Therapeutics.

Prior to joining PBM Capital, Sean was the Executive Vice President for New Business Development and M&A for PBM Products which was sold to Perrigo Company (NASDAQ: PRGO) for over $800 million. Sean began his career in finance at First Boston and Greenwich Capital Markets. He received his BA in Business Economics from Brown University.